Login to Your Account

Vertex raises outlook on Kalydeco as analysts keep eyes on Orkambi uptake

By Michael Fitzhugh
Staff Writer

Thursday, July 30, 2015

Rising Kalydeco (ivacaftor) sales carried Vertex Pharmaceuticals Inc.'s second quarter revenue 20 percent higher, giving the company confidence to raise projected sales of the CF drug.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription